In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC)
have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-…

Treating head and neck cancer patients with systemic therapy is challenging because of tumor
related, patient related and treatment related factors. In this review, we aim to summarize …

… in the use of precision immunotherapy of head and neck squamous cell carcinoma. Using
next-… therapeutic efficacy and fulfill the promise of precision therapy of head and neck cancer. …

… therapy including surgery, radiation and chemotherapy. Molecular targeted therapies with
… The key deregulated signaling pathways in head and neck squamous cell carcinoma (…

… in 2012, including patients with squamous cell carcinoma of the lung.27, 28 … cell carcinoma
of the lung and the head and neck generated interest in immune checkpoint therapy for …

… settings in advanced head and neck cancer, and it is the only targeted therapy approved for
… targeted therapies, focusing on those that have potential to impact the management of head …

… , HPV-related oropharyngeal carcinoma has a favorable … HPV-unrelated head and neck
squamous cell carcinoma (eg, 5-… more likely to experience chronic therapy-induced morbidity. …

… deployment of new molecular targeted therapies. Given the recent approval … cell death-1
in head and neck squamous cell carcinoma, it remains to be determined how targeted therapy …

… Importance of the field: EGFR is an established therapeutic target in head and neck
squamous cell carcinoma (HNSCC). The EGFR-targeting monoclonal antibody cetuximab (Erbitux™, …

… squamous cell carcinoma of the head and neck. Excluded studies included the following: (1)
therapy other than cetuximab, (2) cancers outside of head and neck, (3) non–squamous cell …